Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes

Reuters

Nov 04, 2025

Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes

Bio-Techne Corporation, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer $(SITC)$ 2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET™ platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG13776) on November 04, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580273083"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580273083\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580273083?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580273083","market":"fut","top_or_hot":-1,"title":"Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bio-<a href=\"https://laohu8.com/S/TECH\">Techne Corporation</a>, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET™ platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG13776) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bio-<a href=\"https://laohu8.com/S/TECH\">Techne Corporation</a>, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET™ platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG13776) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z6F94.USD","symbol_name":"Legg Mason Royce - US Smaller Companies A Acc USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL3YPfZf:1","article_id":"2580273083","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580273083","pubTimestamp":1762264968,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bio-Techne Corporation, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer  2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.Disclaimer: This news brief was created by Public Technologies  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4121":"生命科学工具和服务","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4585":"ETF&股票定投概念","BK4588":"碎股","TECH":"Techne Corporation"},"translate_title":"Bio-Techne公布人工智能驱动的空间生物学数据预测黑色素瘤免疫治疗结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":0.9},"content_text":"Bio-Techne Unveils AI-Driven Spatial Biology Data Predicting Melanoma Immunotherapy Outcomes\n    \n\n        Bio-Techne Corporation, in collaboration with Nucleai, has announced the presentation of pivotal data from the SECOMBIT clinical trial at the upcoming Society for Immunotherapy of Cancer $(SITC)$ 2025 Annual Meeting. The study, selected as one of the top 150 abstracts out of over 1,200 submissions, highlights the use of Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platform to identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. Researchers used the COMET™ platform and a 28-plex multiplex immunofluorescence panel to profile 42 pre-treatment biopsies from metastatic melanoma patients. The analysis revealed immune cell interactions correlated with clinical outcomes such as progression-free and overall survival across three different treatment arms. These results will be presented at SITC 2025, with visual data from the study to be featured in Poster #528.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG13776) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}